Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
NCT ID: NCT06640517
Last Updated: 2025-06-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE3
Total Enrollment
140 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-08-08
Study Completion Date
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis. The study will have randomized, double-blind, placebo-controlled study with open-arm comparison.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis
NCT07008547
Plaque Psoriasis
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
NCT04911751
Psoriatic Plaque
COMPLETED
PHASE2
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
NCT06142357
Moderate-to-severe Plaque Psoriasis
ACTIVE_NOT_RECRUITING
A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate
NCT01251614
Plaque Psoriasis
COMPLETED
PHASE3
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
NCT04123795
Moderate Chronic Plaque Psoriasis
Severe Chronic Plaque Psoriasis
Mixed Guttate/Plaque Psoriasis
RECRUITING
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following screening, subjects will be randomized to receive either netakimab, placebo or adalimumab in a 2:1:2 ratio and enter the main study period.
During the main study period, subjects will receive therapy with netakimab/placebo (double-blind arms) or adalimumab (open-label arm), which will be administered subcutaneously until week 12.
At Week 12, after completion of all scheduled procedures subjects in groups netakimab/placebo will continue to receive open-label netakimab for up to week 58, subjects in group adalimumab will switch to open-label adalimumab after 8-week "washout" period.
At Week 58, after completion of all scheduled procedures subjects with sPGA ≤1 will be re-randomised to recieve either netakimab or placebo in double-blind maner. The subjects with \>1 will continue to recieve open-label netakimab.
During the main study period, subjects will receive therapy with netakimab/placebo (double-blind arms) or adalimumab (open-label arm), which will be administered subcutaneously until week 12.
At Week 12, after completion of all scheduled procedures subjects in groups netakimab/placebo will continue to receive open-label netakimab for up to week 58, subjects in group adalimumab will switch to open-label adalimumab after 8-week "washout" period.
At Week 58, after completion of all scheduled procedures subjects with sPGA ≤1 will be re-randomised to recieve either netakimab or placebo in double-blind maner. The subjects with \>1 will continue to recieve open-label netakimab.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Plaque Psoriasis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NTK
netakimab given subcutaneously during main period, open-label period and treatment discontinuation period
Group Type
EXPERIMENTAL
Netakimab
Intervention Type
DRUG
netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
PBO
placebo given subcutaneously during main period and treatment discontinuation period
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
placebo will be administered subcutaneously at a scheme masking netakimab treatment
ADA
adalimumab given subcutaneously during main period
Group Type
ACTIVE_COMPARATOR
Adalimumab
Intervention Type
DRUG
adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Netakimab
netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
Intervention Type
DRUG
Placebo
placebo will be administered subcutaneously at a scheme masking netakimab treatment
Intervention Type
DRUG
Adalimumab
adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Written informed consent of the legal representative and the subject to participate in the study (the study subject signs the appendix to the information sheet for the legal representative of the clinical study subject with informed consent form).
2. For Stage 1 only: age ≥12 and \<18 years at the time of randomization.
3. For Stage 2 only: age ≥6 and \<12 years at the time of randomization.
4. A diagnosis of moderate to severe plaque psoriasis with a disease duration of the disease being at least 3 months before the signing of the ICF.
5. Subjects who are candidates for phototherapy or systemic therapy for psoriasis (including non-responders to systemic therapy or phototherapy), in the opinion of the Investigator, or who did not achieve adequate disease control with topical agents.
6. At the time of the screening examination, the body surface area affected by psoriasis is \>10% of the body surface area (BSA), the Psoriasis Area and Severity Index (PASI) score is ≥12, and the static Physician's Global Assessment (sPGA) score is ≥3.
7. Subjects with the normal laboratory test results at screening.
8. Subjects with a negative whole blood IFN-γ release test.
9. The ability of the subject and his/her legal representative, in the Investigator's opinion, to perceive information and follow the Protocol procedures.
10. Willingness of subjects and their sexual partners of childbearing potential to use highly effective methods of contraception from the signing of the ICF to 12 weeks after the last dose of the investigational product. This requirement does not apply to subjects who have not reached sexual maturity or who have undergone surgical sterilization. The subject's legal representative must consent to the subject's use of contraception.
2. For Stage 1 only: age ≥12 and \<18 years at the time of randomization.
3. For Stage 2 only: age ≥6 and \<12 years at the time of randomization.
4. A diagnosis of moderate to severe plaque psoriasis with a disease duration of the disease being at least 3 months before the signing of the ICF.
5. Subjects who are candidates for phototherapy or systemic therapy for psoriasis (including non-responders to systemic therapy or phototherapy), in the opinion of the Investigator, or who did not achieve adequate disease control with topical agents.
6. At the time of the screening examination, the body surface area affected by psoriasis is \>10% of the body surface area (BSA), the Psoriasis Area and Severity Index (PASI) score is ≥12, and the static Physician's Global Assessment (sPGA) score is ≥3.
7. Subjects with the normal laboratory test results at screening.
8. Subjects with a negative whole blood IFN-γ release test.
9. The ability of the subject and his/her legal representative, in the Investigator's opinion, to perceive information and follow the Protocol procedures.
10. Willingness of subjects and their sexual partners of childbearing potential to use highly effective methods of contraception from the signing of the ICF to 12 weeks after the last dose of the investigational product. This requirement does not apply to subjects who have not reached sexual maturity or who have undergone surgical sterilization. The subject's legal representative must consent to the subject's use of contraception.
Exclusion Criteria
1\. Erythrodermic, pustular, guttate psoriasis, drug-induced psoriasis or any other skin diseases (e.g. eczema) at screening that can affect/complicate the assessment of psoriasis treatment with the investigational product.
2\. Use of the following medications:
1. Prior use of drugs based on monoclonal antibodies against interleukin-17 or its receptor.
2. Prior use of adalimumab.
3. Prior use of monoclonal antibodies or their fragments within 12 weeks before signing the ICF.
4. Use of systemic non-biological medicinal products including methotrexate, sulfasalazine, cyclosporine or acitretin within 4 weeks prior to the date of signing the ICF. If previously used systemic non-biologic drugs are discontinued for any reason, the screening period can be extended for up to 8 calendar weeks, during which new systemic non-biologic drugs are not prescribed.
5. Use of phototherapy (including selective phototherapy \[UV-B\] and photochemotherapy \[PUVA\]) less than 4 weeks before the date of signing the ICF.
6. Vaccination with live vaccines at any time within 12 weeks prior to signing the ICF or an expected need for such vaccination during the study.
3\. Recurrent, chronic, or any other active infection in which, in the opinion of the Investigator, the investigational product may harm the study subject.
4\. Sepsis or risk of sepsis. 5. Positive HIV-1 or HIV-2 test. 6. HBV/HCV infections (for details, see Section 6.5.7.2). 7. Established diagnosis or a history of immunodeficiency syndrome (e.g., severe combined immunodeficiency syndrome, T and B cell deficiency syndromes, chronic granulomatous disease), or an infection characteristic of an immunodeficiency (e.g., pneumocystis pneumonia, histoplasmosis or coccidioidomycosis) at the time of signing the ICF.
8\. Diagnosis of tuberculosis, including a history of tuberculosis. 9. A clinically significant infection caused by the varicella-zoster virus within 12 weeks prior to signing the ICF.
10\. Body temperature ≥38°C at the screening. These subjects may be re-screened, but not earlier than 4 weeks after the first screening.
11\. Other concomitant medical conditions that continued at the time of the screening examination, which increase the risk of adverse events during the study or may affect the evaluation of psoriasis symptoms, mask, enhance, or alter the symptoms of psoriasis, or cause clinical or laboratory symptoms similar to those of psoriasis and confirmed by the source documentation:
1. Active inflammatory diseases or aggravation of chronic inflammatory diseases other than psoriasis.
2. Functional class III-IV stable angina of effort, unstable angina or a history of myocardial infarction within 1 year before signing the IC.
3. Moderate to severe cardiac failure (NYHA class III-IV).
4. Grade 2 hypertension.
5. A history of atopic asthma, angioedema.
6. Moderate to severe respiratory failure, Grade 3/4 chronic obstructive pulmonary disease.
7. Decompensated diabetes mellitus; decompensated hypothyroidism, decompensated thyrotoxicosis.
8. Significant systemic autoimmune diseases according to the Investigator.
9. A history of Crohn's disease, ulcerative colitis.
10. Any other underlying conditions (including but not limited to metabolism, hematology, renal, hepatic, pulmonary, neurological, endocrine, cardiac, and gastrointestinal disorders; infections) that may, in the Investigator's opinion, affect the course of psoriasis, affect the assessment of its symptoms, or put the subject using the study therapy at unacceptable risk.
12\. Malignant and lymphoproliferative diseases, including lymphoma; symptoms indicating the development of a lymphoproliferative disease (such as lymphadenopathy and/or splenomegaly), except for those previously excluded by a biopsy.
13\. History of allergic reactions (anaphylactic shock or allergy to 2 or more drugs).
14\. Known allergy or intolerance to monoclonal antibody products or any components of the investigational product.
15\. Major surgery within 30 days before the screening, or a major surgery scheduled at any time during the study.
16\. Severe infections (including those that required hospitalization or parenteral antibacterial, antimycotic, or antiprotozoal agents) within 6 months prior to signing the ICF.
17\. Use of systemic antibacterial, antimycotic, or antiprotozoal agents within 2 months before signing the ICF.
18\. More than 4 episodes of respiratory infections over the past 6 months prior to signing the ICF.
19\. Any concomitant diseases in which, in the Investigator's opinion, the study therapy may harm the subject.
20\. Signs of premature puberty at the screening examination. 21. Pregnancy, breastfeeding, or planning pregnancy while participating in the study.
22\. Any psychiatric disorder, including a history of severe depressive disorders and/or suicidal thoughts, which, in the opinion of the Investigator, may pose an excessive risk to the subject or affect the subject's ability to follow the Protocol.
23\. Drug addiction, alcoholism, or abuse with drugs or other psychoactive substances (including a history of such disorders).
24\. Simultaneous participation in other clinical studies, as well as previous participation in other clinical studies less than 3 months before signing the ICF, prior participation in this study.
25\. Use of any other investigational products at the time of signing the ICF or less than 28 days before the planned date of signing the ICF or 5 half-lives (whichever is longer) before the date of signing the ICF.
2\. Use of the following medications:
1. Prior use of drugs based on monoclonal antibodies against interleukin-17 or its receptor.
2. Prior use of adalimumab.
3. Prior use of monoclonal antibodies or their fragments within 12 weeks before signing the ICF.
4. Use of systemic non-biological medicinal products including methotrexate, sulfasalazine, cyclosporine or acitretin within 4 weeks prior to the date of signing the ICF. If previously used systemic non-biologic drugs are discontinued for any reason, the screening period can be extended for up to 8 calendar weeks, during which new systemic non-biologic drugs are not prescribed.
5. Use of phototherapy (including selective phototherapy \[UV-B\] and photochemotherapy \[PUVA\]) less than 4 weeks before the date of signing the ICF.
6. Vaccination with live vaccines at any time within 12 weeks prior to signing the ICF or an expected need for such vaccination during the study.
3\. Recurrent, chronic, or any other active infection in which, in the opinion of the Investigator, the investigational product may harm the study subject.
4\. Sepsis or risk of sepsis. 5. Positive HIV-1 or HIV-2 test. 6. HBV/HCV infections (for details, see Section 6.5.7.2). 7. Established diagnosis or a history of immunodeficiency syndrome (e.g., severe combined immunodeficiency syndrome, T and B cell deficiency syndromes, chronic granulomatous disease), or an infection characteristic of an immunodeficiency (e.g., pneumocystis pneumonia, histoplasmosis or coccidioidomycosis) at the time of signing the ICF.
8\. Diagnosis of tuberculosis, including a history of tuberculosis. 9. A clinically significant infection caused by the varicella-zoster virus within 12 weeks prior to signing the ICF.
10\. Body temperature ≥38°C at the screening. These subjects may be re-screened, but not earlier than 4 weeks after the first screening.
11\. Other concomitant medical conditions that continued at the time of the screening examination, which increase the risk of adverse events during the study or may affect the evaluation of psoriasis symptoms, mask, enhance, or alter the symptoms of psoriasis, or cause clinical or laboratory symptoms similar to those of psoriasis and confirmed by the source documentation:
1. Active inflammatory diseases or aggravation of chronic inflammatory diseases other than psoriasis.
2. Functional class III-IV stable angina of effort, unstable angina or a history of myocardial infarction within 1 year before signing the IC.
3. Moderate to severe cardiac failure (NYHA class III-IV).
4. Grade 2 hypertension.
5. A history of atopic asthma, angioedema.
6. Moderate to severe respiratory failure, Grade 3/4 chronic obstructive pulmonary disease.
7. Decompensated diabetes mellitus; decompensated hypothyroidism, decompensated thyrotoxicosis.
8. Significant systemic autoimmune diseases according to the Investigator.
9. A history of Crohn's disease, ulcerative colitis.
10. Any other underlying conditions (including but not limited to metabolism, hematology, renal, hepatic, pulmonary, neurological, endocrine, cardiac, and gastrointestinal disorders; infections) that may, in the Investigator's opinion, affect the course of psoriasis, affect the assessment of its symptoms, or put the subject using the study therapy at unacceptable risk.
12\. Malignant and lymphoproliferative diseases, including lymphoma; symptoms indicating the development of a lymphoproliferative disease (such as lymphadenopathy and/or splenomegaly), except for those previously excluded by a biopsy.
13\. History of allergic reactions (anaphylactic shock or allergy to 2 or more drugs).
14\. Known allergy or intolerance to monoclonal antibody products or any components of the investigational product.
15\. Major surgery within 30 days before the screening, or a major surgery scheduled at any time during the study.
16\. Severe infections (including those that required hospitalization or parenteral antibacterial, antimycotic, or antiprotozoal agents) within 6 months prior to signing the ICF.
17\. Use of systemic antibacterial, antimycotic, or antiprotozoal agents within 2 months before signing the ICF.
18\. More than 4 episodes of respiratory infections over the past 6 months prior to signing the ICF.
19\. Any concomitant diseases in which, in the Investigator's opinion, the study therapy may harm the subject.
20\. Signs of premature puberty at the screening examination. 21. Pregnancy, breastfeeding, or planning pregnancy while participating in the study.
22\. Any psychiatric disorder, including a history of severe depressive disorders and/or suicidal thoughts, which, in the opinion of the Investigator, may pose an excessive risk to the subject or affect the subject's ability to follow the Protocol.
23\. Drug addiction, alcoholism, or abuse with drugs or other psychoactive substances (including a history of such disorders).
24\. Simultaneous participation in other clinical studies, as well as previous participation in other clinical studies less than 3 months before signing the ICF, prior participation in this study.
25\. Use of any other investigational products at the time of signing the ICF or less than 28 days before the planned date of signing the ICF or 5 half-lives (whichever is longer) before the date of signing the ICF.
Minimum Eligible Age
6 Years
Maximum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocad
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation
Barnaul, , Russia
Site Status
State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary"
Chelyabinsk, , Russia
Site Status
Limited Liability Company "Health Azbuka Medical Center"
Kazan', , Russia
Site Status
State Autonomous Healthcare Institution "Republic Clinical Dermatovenerologic Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor Ge"
Kazan', , Russia
Site Status
State Autonomous Healthcare Institution "Kuzbass Clinical Dermatovenerological Dispensary"
Kemerovo, , Russia
Site Status
Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation
Kirov, , Russia
Site Status
State budgetary healthcare institution "Clinical Dermatovenerologic Dispensary" of the Ministry of Health of the Krasnodar Territory
Krasnodar, , Russia
Site Status
Federal State Autonomous Institution "National Medical Research Center for Children's Health" of the Ministry of Health of the Russian Federation
Moscow, , Russia
Site Status
Federal State Budgetary Institution "State scientific centre of dermatovenerology and cosmetology" of the Ministry of health of Russian Federation, Nizhny Novgorod branch
Nizhny Novgorod, , Russia
Site Status
Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation
Saint Petersburg, , Russia
Site Status
Limited Liability Company "PiterKlinika"
Saint Petersburg, , Russia
Site Status
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation
Tomsk, , Russia
Site Status
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University"
Tomsk, , Russia
Site Status
State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology"
Yekaterinburg, , Russia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Russia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCD-085-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
NCT05096364
COMPLETED
PHASE2
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03412747
COMPLETED
PHASE3
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043
COMPLETED
PHASE3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT04772079
RECRUITING
PHASE3
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
NCT02129777
COMPLETED
PHASE2
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512
COMPLETED
PHASE3
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
NCT02207244
COMPLETED
PHASE3
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
NCT04612699
COMPLETED
PHASE2
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
NCT03073200
COMPLETED
PHASE3
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03240809
ACTIVE_NOT_RECRUITING
PHASE4
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115
ACTIVE_NOT_RECRUITING
PHASE3
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03410992
COMPLETED
PHASE3
A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
NCT05174598
COMPLETED
PHASE3
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
NCT03025542
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
NCT06066125
COMPLETED
PHASE3
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
NCT02698475
COMPLETED
PHASE3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
NCT03451851
ACTIVE_NOT_RECRUITING
PHASE3
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00646191
COMPLETED
PHASE2
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
NCT01090427
COMPLETED
PHASE3
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645814
COMPLETED
PHASE2
Treatment of Moderate to Severe Plaque Psoriasis
NCT06542614
COMPLETED
PHASE2
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
NCT02905006
COMPLETED
PHASE2
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00338754
COMPLETED
PHASE2/PHASE3
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199
RECRUITING
PHASE3